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A B S T R A C T
Background: Heterozygous females with Fabry disease have a wide range of clinical phenotypes depending on
the nature of their mutation and their X-chromosome inactivation pattern; it is therefore important to examine
outcomes of enzyme replacement therapy (ERT) in the female patient population specifically. This paper pre-
sents the findings of a systematic literature review of treatment outcomes with ERT in adult female patients.
Methods: A comprehensive systematic literature review was conducted through January 2017 to retrieve pub-
lished papers with original data on ERT in the treatment of Fabry disease. The review included all original
articles that presented ERT outcomes data on patients with Fabry disease, irrespective of the study type.
Results: Clinical evidence for the efficacy of ERT in female patients was available from 67 publications including
six clinical trial publications, and indicates significant reductions in plasma and urine globotriaosylceramide
(GL-3) accumulation (in female patients with elevated pre-treatment levels) and improvements in cardiac
parameters and quality of life (QoL). To date, data are insufficient to conclude on the effects of ERT on the
nervous system, gastrointestinal manifestations, and pain in female patients with Fabry disease.
Conclusions: This review of available literature data demonstrates that ERT in adult female patients with Fabry
disease has a beneficial effect on GL-3 levels and cardiac outcomes. The current evidence also suggests that ERT
may improve QoL in this patient population, though further studies are needed to examine these results.
https://doi.org/10.1016/j.ymgme.2018.09.007
Received 5 April 2018; Received in revised form 19 September 2018; Accepted 20 September 2018
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BPI, Brief Pain Inventory; CR, case report; CT, clinical trial; ECG,
electrocardiogram/electrocardiography; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EMA, European Medicines Agency; EOW, every other week;
ERT, enzyme replacement therapy; FOS, Fabry Outcome Survey; GFR, glomerular filtration rate; GI, gastrointestinal; GL-3, globotriaosylceramide; LVEF, left ven-
tricular ejection fraction; LVH, left ventricular hypertrophy; LVM, left ventricular mass; LVMi, left ventricular mass index; LVWT, left ventricular wall thickness; lyso-
GL-3, globotriaosylsphingosine; MG, mixed-gender; MRI, magnetic resonance imaging; NYHA, New York Heart Association; OS, observational study/studies; QoL,
quality of life; SF-36, 36-item Short Form Health Survey; TIA, transient ischaemic attack; WMH, white matter hyperintensities
⁎ Corresponding author at: French Referral Center for Fabry disease, Division of Medical Genetics, University of Versailles Hôpitaux Universitaires Paris Ile de
France Ouest, AP-HP, 104 boulevard Raymond Poincaré, 92380 Garches, France.
E-mail address: dominique.p.germain@aphp.fr (D.P. Germain).
Molecular Genetics and Metabolism 126 (2019) 224–235
Available online 27 September 2018
1096-7192/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
1. Introduction
Fabry disease (OMIM #301500) is an X-linked lysosomal disease
caused by a mutation in the GLA gene (OMIM #300644; HGNC 4296)
encoding the acid hydrolase α-galactosidase [1]. This leads to the ac-
cumulation of globotriaosylceramide (GL-3) and its deacylated product
globotriaosylsphingosine (lyso-GL-3) in plasma and urine as well as in a
wide range of cell types, particularly the kidney, heart, and nervous
system, resulting in progressive organ damage [1,2]. Fabry disease can
be treated with enzyme replacement therapy (ERT) with recombinant
α-galactosidase, available for more than a decade.
There are two preparations available: agalsidase alfa (Replagal®)
administered at the licensed dose of 0.2mg/kg body weight; and
agalsidase beta (Fabrazyme®) administered at the licensed dose of
1.0 mg/kg body weight. Both preparations are administered in-
travenously every other week (EOW) [3,4]. ERT with recombinant α-
galactosidase was approved in Europe in 2001. Agalsidase alfa and
agalsidase beta are available in most European countries, and in Asia,
Australia, and Canada. Agalsidase beta was approved by the US Food
and Drug Administration in 2003.
Clinical evidence suggests that ERT can slow or delay organ damage
and improve clinical signs and symptoms of Fabry disease, such as
kidney dysfunction, neuropathic pain, gastrointestinal (GI) outcomes,
and cardiac manifestations [1,4,5]. Literature reviews have been con-
ducted to consolidate and report the efficacy and safety of ERT in Fabry
disease [6,7]. However, much of the available literature focused on
reporting outcomes in male patients. Females are heterozygotes for the
GLA mutation [8,9], experience X-chromosome inactivation, are much
harder to diagnose as they can be asymptomatic or have only mild
symptoms, often have plasma α-galactosidase activity within the
normal range, and typically present with symptoms later than males.
Data on the effect of ERT in females can be deduced from publications
that either included a large proportion of female patients in their study
population, or reported the effects in males and females separately.
However, to our knowledge, no previous systematic review has at-
tempted to summarize all the published evidence regarding the effect of
any type of ERT regimen on all Fabry-related outcomes specifically in
female Fabry patients.
We conducted a comprehensive systematic literature review of all
original articles investigating the effect of ERT in the treatment of Fabry
disease published through January 2017 [10]. In this paper, we present
the findings specifically in female patients with Fabry disease.
2. Methods
The full methodology for the systematic literature searches and
analysis that were performed has been published in this issue [10]. The
literature search included articles published up to and including Jan-
uary 2017. The results of the systematic literature analysis for the fe-
male population are described in this article; publications summarizing
the findings of the literature analysis for the male [11] and paediatric
populations [12], as well as a position statement on therapeutic goals in
Fabry disease based on the outcomes of an expert consensus panel [13]
are also published in this issue.
The outcomes that were selected for analysis included plasma and
urine (lyso-)GL-3 levels, GL-3 histology, measures of kidney and heart
function as well as heart morphology. Other outcomes included auto-
nomic, peripheral, and central nervous system parameters in addition
to GI outcomes, pain, and quality of life (QoL).
Results are described for the approved dose regimens of agalsidase
alfa (0.2 mg/kg EOW) and agalsidase beta (1.0mg/kg EOW) unless
specified otherwise. Publications describing results of studies in which
data from patients treated with agalsidase alfa and agalsidase beta were
combined or in which the ERT type was not specified are referred to in
the analysis as ‘mixed-ERT’ publications.
3. Results
3.1. Female population and publication overview
Publications that were included in the systematic literature analysis
presenting ERT outcomes data for female patients specifically are listed
in Supplementary Table 1a. Overall, for agalsidase alfa there were five
publications from clinical trials (CT) (one from a Grade 1a randomized
controlled trial [RCT] and four from Grade 1c single-arm clinical trials),
ten publications from observational studies (OS) (of which three cov-
ered Grade 2 prospective OS publications and seven Grade 3 retro-
spective OS publications), and one case series (Grade 4 evidence). For
agalsidase beta, there were no CT publications, seven OS publications
(two from Grade 2 prospective OS publications and five from Grade 3
retrospective OS publications), four case series (Grade 4 evidence), and
10 case reports (CRs). There were no CT publications, 18 OS publica-
tions (seven Grade 2 prospective OS publications and 11 Grade 3 ret-
rospective OS publications), four case series (Grade 4 evidence), and
one CR describing mixed-ERT clinical outcomes.
Supplementary Table 1b lists the publications included in this
analysis that presented ERT outcomes data for mixed-gender (MG)
populations including ≥50% female patients. For agalsidase alfa there
were no CT publications, four OS publications (one Grade 2 prospective
OS publication and three Grade 3 retrospective OS publications), and
no CRs. For agalsidase beta there were no CT publications, one pub-
lication from a Grade 2 prospective OS publication, and no CRs. There
was one Grade 1c single-arm clinical trial publication, seven OS pub-
lications (five Grade 2 prospective OS publications and two Grade 3
retrospective OS publications), and no CRs presenting outcomes from
mixed-ERT in MG populations.
The main findings regarding clinical outcomes of treatment with
approved doses of agalsidase beta or agalsidase alfa in female patients
with Fabry disease are summarized in Table 1.
3.2. GL-3 accumulation
3.2.1. Plasma GL-3
3.2.1.1. Agalsidase alfa 0.2 mg/kg EOW. One RCT [18] and three single-
arm CT publications [14,16,17] reported plasma GL-3 outcomes data
after treatment with agalsidase alfa in female patients. One single-arm
open-label CT publication described no changes in plasma GL-3 levels
when patients who were either ERT-naïve (n=15) or previously
exposed to agalsidase beta (n=31) received agalsidase alfa [17]. In
the ERT-naïve group, 14 patients had data at baseline and three patients
had data available after 24months of treatment; in the switch group,
data were available for 29 and 19 patients at baseline and 2-year
follow-up, respectively [17]. A significant decrease in mean plasma GL-
3 semi-quantitative scores was reported in a prospective single-arm,
open-label CT of 36 female patients (mean age 47 [range 14–76] years)
who completed 4 years of treatment with agalsidase alfa; in this trial,
72% of patients had elevated GL-3 levels before treatment [16]. The use
of scores, instead of actual concentrations, is a limitation of this study.
In one RCT in which baseline and 1-year post-ERT treatment data were
reported for six patients [18] and another single-arm CT (which
included 15 patients at baseline, mean age 45 [range 20–66] years
and had data for 11 patients after 13months of treatment) [14], the
female patients had normal or only slightly elevated plasma GL-3 levels
before starting ERT and no significant changes were observed. An OS
publication reported no significant change in plasma GL-3 in female
patients who generally had normal levels before starting ERT (seven
patients with baseline and post-12months of agalsidase alfa data) [50]
(Table 2). A CR of a 62-year-old female patient who switched from
agalsidase beta (1.0 mg/kg for 3 years and 5months; 0.7 mg/kg EOW
for 10months) to 0.2 mg/kg EOW agalsidase alfa showed an increase in
plasma GL-3 levels in the first 12months after the switch. However,
after 12months, these levels decreased to levels lower than those seen
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Table 1
Summary of outcomes with agalsidase beta 1.0mg/kg EOW or agalsidase alfa 0.2mg/kg EOW from clinical and observational studies of adult female patients with
Fabry disease.
Outcome Agalsidase alfa 0.2mg/kg EOW Agalsidase beta 1.0 mg/kg EOW
3.1 GL-3 accumulation
3.1.1. Plasma GL-3 ↓ Significant (Whybra et al. 2009 [16]) No data from patients with elevated
baseline levels
[in patients with elevated pre-treatment
levels]
↓ Non-significant (Baehner et al., 2003 [14]) — No change from normal baseline levels
(Bénichou et al., 2009 [30])— No change (Goker-Alpan et al. 2015 [17])
3.1.2. Plasma lyso-GL-3 ↓ Significant (Goker-Alpan et al. 2015 [17 (treatment-naïve patients)] No data from clinical or observational
studies with approved dose of agalsidase
beta
[in patients with elevated pre-treatment
levels]
— No change (Goker-Alpan et al. 2015 [17 (after switch)]
3.1.3. Urinary GL-3 ↓ Significant (Whybra et al. 2009 [16]; Baehner et al., 2003 [14]) No data from clinical or observational
studies with approved dose of agalsidase
beta
[in patients with elevated pre-treatment
levels]
↓ Significance unknown (Whitfield et al. 2005 [19])
— No significant change (Goker-Alpan et al. 2015 [17])
Urinary lyso-GL-3 No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational
studies with approved dose of agalsidase
beta
[in patients with elevated pre-treatment
levels]
3.1.4. GL-3 histology No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational
studies with approved dose of agalsidase
beta
3.2 Renal outcomes
3.2.1. eGFR — No change (Whybra et al. 2009 [16]; Baehner et al. 2003 [14]; Feriozzi
et al. 2012 [24]; Hughes et al. 2011 [26]; Feriozzi et al. 2009 [23]; Beck
et al. 2015 [27]; Kampmann et al. 2015 [28])
— No change (Warnock et al. 2012 [33];
Kim et al. 2016 [34])[compared with decline as with natural
history]
3.2.2. Proteinuria/Albuminuria ↓ Significant in a subgroup of patients with baseline proteinuria levels
> 300mg/day (Whybra et al. 2009 [16])
— No change (Kim et al. 2016 [34])
— No change (Hughes et al. 2011 [26]; Feriozzi et al. 2009 [23]; Kampmann
et al. 2015 [28])
3.3. Cardiac outcomes
3.3.1. LVM/LVMi ↑ Significant (Beck et al. 2015 [27]) ↓ Significant in LVM (Motwani et al. 2012
[32])
↓ Significant in LVM (Tsuboi et al. 2012 [51]; Whybra et al. 2009 [16];
Baehner et al. 2003 [14]; Hughes et al. 2011 [26]; Kampmann et al. 2015
(first 3 years [28])
— No change (Kim et al. 2016 [34])
— Stable LVMi (Goláň et al. 2015 [18]; Kampmann et al. 2015 [28 (after
10 years)])
3.3.2. LVWT ↓ Non-significant (Tsuboi et al. 2012 [51]) ↓ Significant (Motwani et al. 2012 [32])
— Stable (Kampmann et al. 2015 [28])
3.3.3. LVEF ↓ Significant (Kampmann et al. 2015 [28]) — No change (Motwani et al. 2012 [32])
3.3.4. ECG measures ↓ Significant [QRS duration] (Baehner et al., 2003 [14]) ↓ Significant, QTc interval (Motwani et al.
2012 [32])
↑ Significant, P wave duration, PQ interval
(Motwani et al. 2012 [32])
3.3.5. Exercise testing ↓ Significant, NYHA classification (Whybra et al. 2009 [16]) No data from clinical or observational
studies with approved dose of agalsidase
beta
3.4. Nervous system outcomes [sweat
function, heat intolerance, auditory
impairment]
— No change, hearing function (Sergi et al. 2010 [25]) No data from clinical or observational
studies with approved dose of agalsidase
beta
↑ Significant, vestibular function (Palla et al. 2007 [20])
↑ Non-significant, vestibular function (Palla et al. 2003 [15])
3.4.1. Brain MRI findings No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational
studies with approved dose of agalsidase
beta
3.4.2. TIA/Stroke No data from clinical or observational studies with approved dose of
agalsidase alfa
No data from clinical or observational
studies with approved dose of agalsidase
beta
3.5. Pain ↓ Significant, BPI (Whybra et al. 2009 [16]) No data from clinical or observational
studies with approved dose of agalsidase
beta
↓ Significant, pain average/right now (Hoffmann et al. 2007 [22])
↓ Non-significant, pain worst/least (Hoffmann et al. 2007 [22])
— No change (Whitfield et al. 2005 [19]; Sergi et al. 2010 [25]; Hughes et al.
2011 [26])
3.6. GI outcomes ↓ Non-significant, constipation and diarrhoea (Hughes et al. 2011 [26]) No data from clinical or observational
studies with approved dose of agalsidase
beta
3.7. QoL ↑ Significant for SF-36 physical function, role-physical score, and general
health (Baehner et al. 2003 [14])
↑ Significant, SF-36 mental and overall
score (Watt et al. 2010 [31])
↓ Significant for SF-36 general health and vitality (Smid et al. 2011 [49
(switch)])
— No change in EQ-5D/VAS (Hughes et al. 2011 [26]) — No change in SF-36 physical component
summary (Watt et al. 2010 [31])— No change, energy levels (Ghali et al. 2012 [56])
Results are summarized as increase [↑], decrease [↓] or no change from baseline to follow-up after ERT initiation. Significance refers to statistical significance. Results
are not adjusted for differences in study designs, patient characteristics, or disease stage. Case series, case reports, mixed-ERT, non-approved dose regimens, and
mixed-gender studies are not included.
BPI, Brief Pain Inventory; ECG, electrocardiogram; EOW, every other week; eGFR, estimated glomerular filtration rate; EQ-5D, 5-dimension EuroQol questionnaire;
GI, gastrointestinal; GL-3, globotriaosylceramide; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMi, left ventricular mass index; lyso-GL-3,
globotriaosylsphingosine; MRI, magnetic resonance imaging; NYHA, New York Heart Association; QoL, quality of life; QTc, corrected QT interval; SF-36, 36-item
Short Form Health Survey; EQ-VAS, EuroQol-Visual Analogue Scale.
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when the patient was receiving agalsidase beta [52].
In a small Japanese MG study, 11 patients (seven females; mean age
52 years, age at switch 23–68 years) were switched from agalsidase beta
(pre-switch treatment duration 15–77months) to agalsidase alfa. Pre-
switch plasma GL-3 levels were near the normal range for the female
patients but increased 12months after switching to agalsidase alfa [51].
However, a follow-up publication from the same study showed that
plasma GL-3 levels had returned to pre-switch levels 24months after
switching, and this reduction was sustained at 36months [74].
3.2.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, two OS
publications reported plasma GL-3 outcome data; in both publications,
the majority of female patients had GL-3 levels within the normal range
at the start of treatment and no significant changes in plasma GL-3 were
reported [data in 12 patients 30, 50] (Table 2). In one publication, data
were available for nine patients at baseline and eight patients after
1 year of agalsidase beta treatment [50]. A CR that included six female
patients treated with agalsidase beta reported a decrease in plasma GL-
3 in one 35-year-old female patient [37]. A CR of a 62-year-old female
patient who first received agalsidase beta 1.0 mg/kg EOW for 3 years
and 5months, then a reduced dose of 0.7mg/kg EOW for 10months,
and eventually switched to agalsidase alfa showed that the patient had
stable GL-3 levels during treatment with the approved dose of
agalsidase beta [52].
3.2.1.3. Mixed ERT. An OS publication, including data from 28 females
treated for at least 1 year, reported mean plasma GL-3 levels within
normal range at baseline that decreased and remained decreased after
6 years [60].
3.2.2. Plasma lyso-GL-3
3.2.2.1. Agalsidase alfa 0.2 mg/kg EOW. Plasma lyso-GL-3 was reported
as an outcome in female patients in one single-arm open-label CT with
agalsidase alfa [17]. In the ERT-naïve group baseline lyso-GL-3 data
were available for 14 patients and 24-month follow-up data in three
patients. In three ERT-naïve patients with elevated baseline lyso-GL-3,
ERT resulted in a significant reduction, albeit very small, in plasma
lyso-GL-3 levels at 18 and 24months [17]. Lyso-GL-3 levels in female
patients who switched from agalsidase beta to agalsidase alfa were
reported in one CT publication (baseline data in 29 patients), which
Table 2
Plasma GL-3 level outcomes with approved doses of agalsidase alfa and agalsidase beta in adult female patients.
Study, year [reference] Female, n
(%)c
Duration
(months)
Units Baseline Endpoint Overall result (p
value/95% CI)(number of patientsa)
(number of patientsd) (number of patientse)Evidence gradeb
Alfa Goláň et al. 2015 18 (41) 12 nmol/mL Mean: 3.5 Mean: 3.5 NC (95% CI:
[18] (N=44) (n=6) (n= 6) −0.95, 0.93)
Grade 1a
Whybra et al. 2009 40 (100) 48 Plasma GL-3 score6 1.81 [0.58] 1.31 [0.47] ↓ (p < 0.001)
(times above ULN7) (n=36) (n= 36)[16] (N=40)
Patients, n (%) Prevalence stratified by GL-3
score6:
Prevalence stratified
by GL-3 score6:
Grade 1c
1: 7 (19.4) 1: 25 (69.4)
2: 26 (72.2) 2: 11 (30.6)
3: 3 (8.3) 3: 0 (0.0)
(n=36) (n= 36)
Baehner et al. 2003 15 (100) 13 nmol/mL 3.04–17.59 6months: decreased
(NR)
↓ (NS from BL)
(range) (n=15) (n=11)[14] (N=15)
Grade 1c
Goker-Alpan et al. 2015 46 (46) 24 nmol/mL ERT-naïve: ERT-naïve: NC
[17] (N=100) ERT-naïve: 15
(52)
(normal
4.55 ± 3.90)
13.76 ± 2.32 NR NC
Pre-treatment with agalsidase beta
(1 mg/kg EOW; n=71):
55 months (4–146)
Switch: (n=14) (n= 3)
Switch:11.46 ± 0.96 Switch:NR31 (44)
(n=29) (n=19)
Grade 1c
Beta Bénichou et al. 2009 12 (9) Range: μg/mL Above normal in 17% (2
patients)
NC NC (NR)
[30] (N=134) 1.9–60.7 (normal > 7.03) (n=12)
Grade 3
Alfa Van Breemen et al. 2011 [50]
(N=43)
21 (49) 12 μM Alfa 0.2: Alfa 0.2: NC (NR)
Beta (normal < 3.18) 2.82 (2.45–3.28) 2.44 (2.02–3.60) NC (NR)
(n=7) (n= 7)
Beta 1.0: Beta 1.0:
2.53 (1.20–6.76) 1.76 (0.79–3.65)Grade 3
(n=9) (n=8)
Case series, case reports, mixed-ERT publications, paediatric-adult-mixed publications, and publications with other dose regimens are not included. Data are means
[SD] or means± SE or medians (range), unless otherwise indicated. Red font indicates statistically significant changes.
↓, decrease in levels; ↑, increase in levels; BL, baseline; CI, confidence interval; EOW, every other week; ERT, enzyme replacement therapy; GL-3, globo-
triaosylceramide; NC, no change; NR, not reported; NS, not significant; SD, standard deviation; SE, standard error; ULN, upper limit of normal range.
a Total number of patients included in the study who were treated with ERT.
b Study grades defined as follows: Grade 1a randomized controlled trial; Grade 1c single-arm clinical trial; Grade 1a/c randomized controlled trial with single-arm
open-label extension; Grade 2 prospective observational study; Grade 3 retrospective observational study; Grade 4 case series; Grade 5 case report.
c Number of female patients who were treated with ERT.
d Number of female, ERT-treated patients with data for the outcome at baseline.
e Number of female, ERT-treated patients with data for the outcome at endpoint; 6GL-3 values were converted to a 3-point scale as follows: (1) in the normal range;
(2)> normal, but ≤2 x ULN; and (3)> 2 x ULN; 7ULN<3.3 μmol/L or< 4 μg/mL.
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found no significant change after 24months in 19 patients [17]. One OS
publication showed a decrease in plasma lyso-GL-3 levels in seven
patients treated for 12months [50] (Supplementary Table 2). Further, a
CR of a 62-year-old female patient who switched from agalsidase beta
(1.0 mg/kg for 3 years and 5months; 0.7 mg/kg EOW for 10months) to
agalsidase alfa also described that plasma lyso-GL-3 levels were
increased slightly 12months after switching but gradually decreased
to below pre-switch levels [52].
A Japanese, observational MG study including seven female patients
also showed no significant change in plasma lyso-GL-3 levels 36months
after switching from agalsidase beta 1.0mg/kg EOW (pre-switch
treatment duration 15–77months; age at switch 23–68 years) to agal-
sidase alfa 0.2mg/kg EOW [74].
3.2.2.2. Agalsidase beta 1.0 mg/kg EOW. One OS publication showed a
decrease in plasma lyso-GL-3 levels in nine patients treated for
12months [50] (Supplementary Table 2).
3.2.2.3. Mixed ERT. Two publications from a retrospective mixed-ERT
OS also reported significant reductions in plasma lyso-GL-3 over a
median period of 16months compared with pre-treatment levels in
female patients with the classical or the cardiac variant of Fabry
disease. This reduction in lyso-GL-3, however, was not sustained with
increases in lyso-GL-3 observed during long-term follow-up especially
in the female patients with a cardiac-type GLA mutation [six patients,
age at ERT initiation 44–67 years, treatment duration 8–24months
[62], and seven patients 64 [64]. One OS publication reported no
statistical difference in lyso-GL-3 levels before and a median of
1.3 years after the global shortage of agalsidase beta in 3 female
patients who either switched from agalsidase beta to agalsidase alfa
or reduced the dose of agalsidase beta [49].
In MG populations, one mixed-ERT OS reported a slight decrease in
plasma lyso-GL-3 during ERT (median treatment duration 5.7 years) in
21 classically affected female patients who had elevated pre-treatment
lyso-GL-3 levels [77]. One OS publication in 27 female patients with
elevated pre-treatment lyso-GL-3 levels also reported a significant re-
duction in lyso-GL-3 levels after 12months, which was sustained at
6 years' follow-up [60].
3.2.3. Urinary GL-3 and lyso-GL-3
3.2.3.1. Agalsidase alfa 0.2 mg/kg EOW. Three single-arm CT
publications presented urinary GL-3 outcomes with agalsidase alfa in
female patients [14,16,17]. A significant reduction in urinary GL-3
scores was reported after 12months of ERT in a prospective single-arm
open-label trial in 36 female patients (mean age 47 [range 14–76]
years); urinary GL-3 scores decreased during 4 years of follow-up, and
at the end of the study only one female patient had a score above the
normal range [16]. An open-label single-arm trial of ERT with
agalsidase alfa in 15 female patients (mean age 45 [range 20–66]
years) with severe Fabry disease symptoms reported that patients had a
wide range of urinary GL-3 levels before ERT, with the largest
reductions in urinary GL-3 occurring in patients with the highest pre-
treatment levels, but no significant overall differences after 6months of
treatment (n=11) [14]. One single-arm open-label CT reported no
change in urinary GL-3 levels from baseline to 24months in treatment-
naïve patients (baseline data for 14 patients, follow-up data for three
patients) or in patients who switched to agalsidase alfa (data available
for 28 and 18 patients at baseline and follow-up, respectively) [17]. A
small OS publication described decreases in urinary GL-3 after 1 year of
agalsidase alfa in the two female patients included (aged 27 and
41 years) [19] (Supplementary Table 3).
One OS publication reported data from a single 35-year-old female
patient during ERT showing a reduction in urinary lyso-GL-3 at
9months after agalsidase alfa [58].
3.2.3.2. Agalsidase beta 1.0 mg/kg EOW. There was no literature
published regarding the impact of agalsidase beta on urinary GL-3 or
urinary lyso-GL-3 levels in female patients.
3.2.3.3. Mixed ERT. Data from an observational mixed-ERT study
described reductions in urinary GL-3 in female patients during
treatment [60].
3.2.4. Kidney, heart, and other organ GL-3
There were no publications from CTs or OS that reported GL-3
histology data in the kidneys, heart, or other organs after ERT.
3.2.4.1. Agalsidase alfa 0.2 mg/kg EOW. There were no publications
available that described changes in GL-3 levels in the kidneys, heart, or
other organs with agalsidase alfa.
3.2.4.2. Agalsidase beta 1.0 mg/kg EOW. In one case series there was a
10-fold reduction in GL-3 levels in heart tissue after 6months of
agalsidase beta treatment in a 46-year-old female patient [36] who
was originally treated in a multicentre, randomized, placebo-controlled
study [79]. In addition, there were two case reports that provided
histopathological evidence of GL-3 inclusions in placental tissue of
mothers, one pregnant with a boy and the other with a girl, treated with
agalsidase beta during pregnancy, but it remains unclear if treatment
had an effect on the placental tissue [41 (24-year-old patient who
started ERT at the age of 21 years), 43 (37-year-old, with 2-years prior
ERT experience before the pregnancy)].
3.2.4.3. Mixed ERT. There were no publications available that
described changes in GL-3 levels in the kidneys, heart, or other
organs with mixed-ERT regimens.
3.3. Renal outcomes
3.3.1. Estimated glomerular filtration rate (eGFR)
3.3.1.1. Agalsidase alfa 0.2 mg/kg EOW. Two publications from open-
label single-arm CTs of agalsidase alfa reported no decline in eGFR
during treatment in female patients [14,16]. One included 15 severely
affected female patients (mean age 45 [range 20–66] years) treated for
13months [14]. In the other, 36 female patients with an average age of
47 (range 14–76) years reported stabilization of eGFR during 4 years of
ERT [16]. Four observational registry data publications also reported a
minimal loss of eGFR over time with agalsidase alfa [change in
eGFR<1 to −2mL/min/1.73m2/year] [50 female patients with an
average age of 50 years and duration of treatment of 36months (23), 74
females with an average age of 46 years and mean duration treatment
of 7.4 years (24), 78 females who started ERT at age 49 years and were
treated for 4 years [26], and 317 females with a median follow-up of
5 years [27]]. In one of these publications, long-term data from the
Fabry Outcome Survey (FOS) registry on outcomes with agalsidase alfa
showed a trend toward improved mean annualized eGFR slopes in
patients without proteinuria at baseline, although the annual changes
in glomerular filtration rate (GFR) in female patients were within the
normal age-expected range [27]. One OS publication reported
stabilization in eGFR in 24 female patients (average age 39 years)
treated with agalsidase alfa for 10 years [28] (Supplementary Table 4).
The main findings from MG studies with ≥50% female patients are
summarized as follows: a small OS, which studied the effects of agal-
sidase alfa in subjects from an extended single family group (including
11 females with ages ranging from 21 to 56 years), reported a sig-
nificant improvement in eGFR after 6months of ERT [72]. Two papers
from the same OS, in which seven of 11 patients were female (mean age
52 years), showed that eGFR remained stable during 36months of
follow-up after switching from agalsidase beta to agalsidase alfa
[51,74]. Another CR with a 62-year-old female patient showed that
after switching from agalsidase beta (1.0mg/kg for 3 years and
5months; 0.7 mg/kg EOW for 10months) to agalsidase alfa eGFR
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remained stable at the decreased level (2-year post-switch follow-up)
[52]. It is important to note when reviewing this evidence that the
inclusion of male patient data in the eGFR outcomes will impact the
results, as male patients typically have more renal involvement than
females [80].
3.3.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one Fabry
Registry publication reported a decrease in eGFR in 62 female patients
treated with ERT although no statistics were provided [33]. ERT was
started at a median of age 43 years and patients were followed for a
mean of 4 years [33]. One OS publication reported no change in eGFR
in four female patients (age at treatment 22, 39, 48, and 48 years) with
normal eGFR levels at baseline who received agalsidase beta (for a
range of 7–10 years). In these patients, dose reduction of agalsidase
beta to 0.25 and 0.5mg/kg EOW did not have an effect on eGFR [34]
(Supplementary Table 4). Three CRs also note that eGFR was stable in
female patients during agalsidase beta treatment [one 29-year-old
patient, 10months after ERT initiation [39], one 37-year-old patient
treated for over 2 years [42], 46], with one CR of a 62-year-old female
patient with up to 12 years of follow-up [46]. In one case study, eGFR
increased slightly in two female patients (26 and 29 years old) treated
with agalsidase beta throughout pregnancy (an increase in eGFR is a
normal feature of pregnancy) [35]. Another CR with one 62-year-old
female patient showed a decrease in eGFR after 2 years on agalsidase
beta [52]. One CR of a 29-year-old patient with marked proteinuria at
baseline noted resolution of renal dysfunction after 1 year of agalsidase
beta treatment [45].
3.3.1.3. Mixed ERT. Publications of data from mixed-ERT studies also
show that ERT is associated with stable eGFR in female patients,
reporting no or minimal declines in eGFR in line with normal age-
related changes in renal function [one 71-year-old female patient
treated for 12months [57], 17 women, 11 with classic and 6 cardiac
phenotypes who started ERT aged 33–79 years and were treated for
6–26months (62), 65, 52 ERT-naïve females, mean age 52 years (66)];
one study reported an improvement in eGFR in 103 female ERT-treated
patients without proteinuria at baseline [63]. One retrospective OS
publication with 28 female patients (average age at baseline 52 years)
showed that eGFR significantly declined over time, with evidence of
greater renal involvement at baseline (mean treatment duration was
80months) [78]. One OS publication in 18 female patients showed no
significant change in the slope of eGFR loss a median of 1.3 years after
switching from agalsidase beta to agalsidase alfa or to reduced-dose
agalsidase beta [49]; the slope of eGFR loss in both ERT treatment
periods (pre- and post-switch) was within the range found in age-
related GFR loss in the general population. Data from two CRs further
support the findings that ERT is associated with eGFR improvement or
stabilization in female ERT-treated patients [four patients with age at
ERT initiation of 21–52 years and duration of ERT 2.8–11 years (53),
and one 42-year–old [70]].
3.3.2. Albuminuria/Proteinuria
3.3.2.1. Agalsidase alfa 0.2 mg/kg EOW. One prospective single-arm
open-label CT publication of agalsidase alfa in 36 females (mean age 47
[range 14–76] years) reported stable proteinuria levels in 33 females,
and a significant improvement in proteinuria after 4 years of treatment
in a subgroup of 11 patients with baseline proteinuria> 300mg/24 h
[16]. In this study, the seven women who received angiotensin-
converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers
(ARBs) during the whole study duration, and had proteinuria levels of
1349 ± 1760mg/24 h at baseline, experienced a 3-fold decline in
proteinuria [16]. Three observational registry studies reported no
overall change in proteinuria outcomes with agalsidase alfa [50
female patients, average age 50 years, duration of treatment
36months [23], 74 females, average age 46 years, mean duration of
treatment 7.4 years [24], 78 females, started ERT age 49 years, treated
for 4 years [26]], and another OS publication also reported no change
in proteinuria in 24 female patients (average age 39 years) with or
without baseline proteinuria after 10 years of treatment [28]
(Supplementary Table 5).
In MG populations, one OS publication of agalsidase alfa noted a
significant decrease in albuminuria in 11 females (ages ranging from 21
to 56 years treated for 6–12months) [72], while another study in-
cluding 46 female patients with proteinuria data showed minimal
changes during treatment of up to 5 years [24]. Another OS publication
showed no change in proteinuria levels in seven female patients over
3 years of follow-up when patients were switched from agalsidase beta
to agalsidase alfa [74]; urinary protein levels were within the normal
physiological range before the switch in ERT regimen [74].
3.3.2.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one OS
publication reported no change in proteinuria in four female patients
with normal proteinuria levels at baseline (age at treatment initiation
ranged from 22 to 48 years, duration of treatment 7–10 years). In these
patients, dose reduction of agalsidase beta to 0.25 and 0.5mg/kg EOW
did not have an effect on proteinuria [34] (Supplementary Table 5).
One CR in a woman who started ERT aged 52 years showed worsening
of proteinuria despite treatment with agalsidase beta for 7 years [44].
In female patients treated with agalsidase beta during pregnancy, one
publication noted stable proteinuria levels in a 21-year-old [48] and
another described improvement in proteinuria levels in two pregnant
(aged 26 and 29 years) patients [35].
3.3.2.3. Mixed ERT. Publications reporting proteinuria outcomes from
mixed-ERT OS in 17 female patients (age at ERT 33–79 years) described
an improvement in albuminuria during ERT treatment (duration
6–26months) [62], a non-significant inverse association between time
on ERT and the likelihood of developing proteinuria (analysis in 158
females) [63], and significant improvements in proteinuria during
treatment (13 patients, mean age 45 years, 6-years follow-up)
compared with a worsening of proteinuria in the 4 untreated patients
(mean age 34 years, 4-years follow-up) [65]. One CR showed that, in
four female patients (age at ERT initiation 21–52 years; duration of ERT
2.8–11 years), ERT resulted in a small increase, decrease, or
stabilization of proteinuria levels [53]. One study showed that
proteinuria during ERT was not affected by the use of ACEi/ARBs [65].
3.4. Cardiac outcomes
3.4.1. Left ventricular mass (LVM)/left ventricular mass index (LVMi)
3.4.1.1. Agalsidase alfa 0.2 mg/kg EOW. LVM was reported as an
outcome in three CT publications, all of which used
echocardiography to determine LVM. A randomized, multicentre,
open-label study including 18 female patients treated for 12months
with one of three different regimens of agalsidase alfa (0.2mg/kg EOW,
0.2 mg/kg weekly, or 0.4mg/kg weekly) reported that treatment with
agalsidase alfa 0.2 mg/kg EOW was associated with a stable LVMi [18].
A prospective single-arm open-label study of 36 women (average age 47
[range 14–76] years) treated with agalsidase alfa for 4 years reported
decreases in LVM; 25 [69%] women in this trial had left ventricular
hypertrophy (LVH) at baseline. Decreases in LVM>20% were reported
in 13 of these 25 patients with seven patients demonstrating decreases
of 10–20% [16]. An open-label single-arm clinical trial of 15 female
patients (mean age 45 [range 20–66] years) treated with agalsidase alfa
for up to 13months reported a progressive decrease in LVM that was
statistically significant after 9months of treatment (n=7) [14]. Two
registry study publications from the FOS reported LVMi outcomes,
determined by echocardiography, after treatment with agalsidase alfa
in 24 [26, treatment duration 4 years] and 93 female patients [27,
median follow-up 5 years]. One of these registry studies reported a
significant decrease in LVMi after 4 years of agalsidase alfa in 12
women with LVH at baseline [26], and the other registry study showed
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that LVH progression significantly increased, and the rate of increase in
LVH was slower with ERT compared with untreated patients [27]. The
annualized rate of LVMi significantly increased in female patients in
this study [27]. An OS publication including 24 ERT-treated females
(average age 39 years) reported no change in LVMi after 10 years of
treatment with agalsidase alfa, although there was an initial significant
improvement between the first and fourth year of treatment [28].
Another OS study including seven females (mean age 52 years) found
that patients switching from agalsidase beta to agalsidase alfa showed
significant reductions in LVMi 12months after switching [51]
(Supplementary Table 6). One CR of a 62-year-old female who had
previously received agalsidase beta (1.0mg/kg for 3 years and
5months; 0.7 mg/kg EOW for 10months) reported stabilization of
LVMi 6months after switching to agalsidase alfa [52].
In MG studies with ≥50% female patients, one OS publication of 17
Fabry patients (of whom 11 were female, with ages ranging from 21 to
56 years) found that agalsidase alfa treatment resulted in an improve-
ment in LVMi after 6months of treatment [72]. Another OS publication,
which assessed 7 female patients (mean age 52 years) switching to
agalsidase alfa, reported that the reduction in LVMi (method of as-
sessment not stated) 12months after switching [51] was maintained
during 36months of follow-up [74]. The patients in this study had been
treated with agalsidase beta 1.0 mg/kg EOW for 1.2–6.5 years before
switching [51]. In contrast, another observational MG study that in-
cluded LVM data for nine female patients did not report any significant
changes in LVMi, assessed using cardiac ultrasound, a median of
1.3 years after switching from agalsidase beta to agalsidase alfa or to
reduced dose agalsidase beta [49].
3.4.1.2. Agalsidase beta 1.0 mg/kg EOW. LVMi outcomes were reported
in one OS publication in a cohort of 22 female patients with a mean age
of 44 years who were treated with agalsidase beta for a median of
36months. 12 patients had LVH at baseline. Treatment resulted in a
significant reduction in LVMi from baseline, as assessed using
echocardiography [32]. One OS publication on four patients (age at
ERT initiation 22–48 years) treated for 7–10 years reported no change
in LVMi [34] (Supplementary Table 6). Similarly, two CRs of female
Fabry patients showed that both patients had stabilized LVH and LVMi
values during 18–27months of agalsidase beta treatment [40 (44-year-
old), (52) (62-year-old)]. One CR also showed that a 62-year-old female
patient had increased LVMi values after 10months of treatment with a
reduced dose of agalsidase beta (0.7 mg/kg EOW) [52]. One CR of a 29-
year-old patient demonstrated an improvement in cardiomegaly after
12months of agalsidase beta [45], although two other CRs in two
female patients found that these patients either developed LVH or
showed LVH progression after agalsidase beta initiation [38 (51-year-
old),44 (52-year-old, 5 years post-ERT follow-up)].
3.4.1.3. Mixed ERT. Echocardiography data on LVMi outcomes from
mixed-ERT OS publications indicate a reduction in LVM and LVMi
during ERT in females with classical Fabry disease [one 71-year-old
female and a 45-year-old female treated for 12months [57], 59, eleven
patients with age at ERT start 33–79 years and treatment duration
6–26months (62),and another reference in eleven patients [64]. A
publication from a mixed-ERT OS (the Canadian Fabry Disease
Initiative) that included 55 women (mean age 52 years) newly
starting on ERT described a reduction in LVMi, measured by
echocardiography, in female patients with proteinuria> 0.5 g/day at
baseline, but an increase in LVMi in females with proteinuria ≤0.5 g/
day [66]. One of the publications (reporting LVMi data on 26 females
aged 47 years) also reported subgroup data showing a slightly greater
improvement in LVM in patients with LVH at baseline [59]. Another
publication from a mixed-ERT study showed that patients with an
abnormal baseline electrocardiogram (ECG) had a significant increase
in LVMi, whereas in patients with a normal ECG there was no change in
LVMi; this report included 12 females with mean age 34 years at
baseline and 41 years at follow-up (median duration of follow-up of
6.4 years) [68]. One CR publication in four females who started ERT
age 21–52 years and were treated for 2.8–11 years also supports these
findings [53].
3.4.2. Left ventricular wall thickness (LVWT)
3.4.2.1. Agalsidase alfa 0.2 mg/kg EOW. An OS publication including
24 females (average age 39 years) reported no significant change in
wall thickness after 10 years of treatment with agalsidase alfa, although
there was a significant improvement after 1 year of treatment [28]. One
small OS publication previously described non-significant
improvements in LVWT variables in the seven female patients (mean
age 52 years) who switched from agalsidase beta to agalsidase alfa [51]
(Supplementary Table 7).
A CR of a 62-year-old showed that wall thickness increased when
the patient treated with agalsidase beta (treatment duration 3 years
5months) was switched to reduced-dose agalsidase beta (treatment
duration 10months) and maintained in the subsequent period on
agalsidase alfa [52].
3.4.2.2. Agalsidase beta 1.0 mg/kg EOW. Wall thickness was assessed
using cardiac echocardiography in an OS publication of agalsidase beta
in 22 female patients (mean age 44 years), 12 of whom had LVH before
starting ERT. After a median duration of 36months, there was a
significant reduction in maximal wall thickness [32] (Supplementary
Table 7). Two CRs observed increases in LVWT in females receiving
agalsidase beta; in both cases the women had lung or cardiac
manifestations of Fabry disease before initiation of ERT in their
fourth or fifth decade [one 51-year–old (38), and another 44-year–old
[40]]. A CR in a 62-year-old female showed that wall thickness
variables increased when the dose of agalsidase beta was reduced
from 1.0mg/kg EOW (treatment duration 3 years and 5months) to
0.7 mg/kg EOW (10months) [52]. A CR reported worsening of LVH in a
cardiac-type 52-year-old female patient treated with agalsidase beta for
5 years [44].
3.4.2.3. Mixed ERT. One mixed-ERT publication reported that six
female patients (started ERT aged 44–67 years) with a mutation
leading to the late-onset cardiac variant of Fabry disease had
reductions in the thicknesses of the intraventricular septum and the
left posterior wall throughout 6–39months of ERT as determined by
echocardiography [62]. One mixed-ERT OS publication showed no
change in posterior wall thickness (data available for 12 females, mean
age 34 years at baseline with a median duration of follow-up of
6.4 years) [68].
3.4.3. Left ventricular ejection fraction (LVEF)
3.4.3.1. Agalsidase alfa 0.2 mg/kg EOW. An OS publication including
24 females (average age 39 years) reported a small but significant
decrease in ejection fraction (EF) after 10 years of treatment with
agalsidase alfa, although mean values remained within normal limits
[28] (Supplementary Table 8).
3.4.3.2. Agalsidase beta 1.0 mg/kg EOW. LVEF was analysed as an
outcome in one prospective OS publication of ERT with agalsidase
beta; no changes were observed (EF was 63% at baseline) after a
median of 36months treatment [32 (22 females, mean age 44 years)]
(Supplementary Table 8). Three CRs described an increase in EF in
patients receiving agalsidase beta [46-year–old with improvement seen
after 2-years of treatment (36), one 44-year-old treated for up to
18months [40], and one 29-year-old patient treated for 12months
(45)].
3.4.3.3. Mixed ERT. One MG, mixed-ERT OS publication including 12
females (age 34 years at baseline) showed no change in LVEF after a
median follow-up duration of 6.4 years [68].
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3.4.4. Electrocardiogram (ECG) measures
3.4.4.1. Agalsidase alfa 0.2 mg/kg EOW. An open-label single-arm CT
that assessed treatment with agalsidase alfa in 15 severely affected
female patients (mean age 45 years [range 20–66] years) reported that
the mean QRS duration decreased progressively but non-significantly
from baseline to 9months (n=5) [14] (Supplementary Table 9).
3.4.4.2. Agalsidase beta 1.0 mg/kg EOW. An OS publication of
agalsidase beta in 22 female patients (mean age 44 years)
demonstrated significant improvement in P wave duration, PQ
interval, and corrected QT interval a after median of 36months of
agalsidase beta treatment [32] (Supplementary Table 9). These findings
are supported by two CRs, one in which a 65-year-old patient reported
resolution of ST segment abnormalities after 1 year of agalsidase beta
[47] and another in which a 46-year-old patient experienced
normalization of PR interval after 6months of agalsidase beta [36].
3.4.4.3. Mixed ERT. A mixed-ERT OS publication in 12 females (mean
age at baseline of 34 years) reported no changes in ECG findings after a
follow-up duration of 6.4 years [68].
3.4.5. Exercise testing
3.4.5.1. Agalsidase alfa 0.2 mg/kg EOW. One prospective single-arm
open-label CT publication in 36 female patients (mean age 47 [range
14–76] years) reported a significant improvement in exercise capacity,
measured using the New York Heart Association (NYHA) classification,
after 4 years of agalsidase alfa treatment [16] (Supplementary
Table 10), and one MG OS publication including 24 females (average
age 39 years) described an improvement in NYHA heart failure
classification following 10 years of agalsidase alfa [28].
3.4.5.2. Agalsidase beta 1.0 mg/kg EOW. One CR of a 62-year-old
female noted a decline in exercise tolerance after at least 3 years of
agalsidase beta [46].
3.4.5.3. Mixed ERT. There were no publications for mixed ERT
describing changes in exercise testing or cardiac function following
treatment.
3.5. Nervous system outcomes
3.5.1. Agalsidase alfa 0.2 mg/kg EOW
For hearing loss and vestibular function, one single-arm CT pub-
lication (21 patients, 8 females with data at baseline, three females with
data after 12-months follow-up) [15], and one OS publication (nine
females, treated for 51.5 months) of agalsidase alfa [25] found no sig-
nificant improvement/stabilization of hearing acuity during ERT
(Supplementary Table 11). However, one OS publication found that
12months of treatment with agalsidase alfa significantly improved
vestibular function in a MG group including 14 ERT-treated females,
although auditory function did not improve during a 5-year follow-up
period [20]. One CR of a 54-year-old female patient treated with
agalsidase alfa in combination with omeprazole observed stabilization
of hearing after 30months of ERT [29].
3.5.1.1. Agalsidase beta 1.0 mg/kg EOW. One CR mentioned the
development of hypohidrosis after ERT initiation in a 51-year-old
patient [38].
3.5.1.2. Mixed ERT. Similarly, two OS publications on mixed ERT
[61,67] found no significant improvement/stabilization of hearing
acuity during ERT. One publication included nine females, with an
average age of 39 years and average follow-up of 47months [61], and
the other 38 females (36 classic phenotype with a median age 48 [range
19–81] years and two non-classic with a median age of 39 [range
31–65] years) who were followed for a median of 7 (range 0–11) years
[67]. In addition, a MG OS publication that included 17 female patients
(median age 51 [range 22–73] years) treated with ERT of unspecified
type for a median of 3.6 years reported no overall change in autonomic
symptom profile scores during ERT [76].
3.5.2. Brain magnetic resonance imaging (MRI) findings (chronic white
matter hyperintensities [WMH])
3.5.2.1. Agalsidase alfa 0.2 mg/kg EOW. No publications reported
WMHs with agalsidase alfa in females or MG populations.
3.5.2.2. Agalsidase beta 1.0 mg/kg EOW. One 62-year-old female, with
small WMHs at baseline, received 12 years of agalsidase beta. After
3 years of therapy she received a pacemaker and did not develop any
new WMHs in the following years [46].
3.5.2.3. Mixed ERT. Several mixed-ERT publications reported the
incidence of WMHs in female patients [54,59,60]. In one publication,
seven female patients with a mean age of 53 years were treated with
ERT for 2 years [56] and in another, 25 females (aged 47 years) had
follow-up MRIs [59]. However, these publications did not describe the
effect of ERT on the pathology. One case series specifically investigated
the impact of ERT on brain structure/function/pathology in 20 patients
(age range 15–66 years). Most patients on agalsidase beta were
switched to agalsidase alfa during shortage. At baseline, five of 20
treated female patients had WMHs, five patients had moderate WMHs,
and one had severe WMHs. During follow-up positron emission
tomography/MRI scans, five patients experienced progressive
pathology [69]. A CR described an ERT-treated 55-year-old female
patient with WMHs who had no increase in WMHs burden after up to
2 years' follow-up [71].
3.5.3. Transient ischaemic attack (TIA)/stroke
There have been no publications that show the effect of ERT on the
incidence of TIA or ischaemic or haemorrhagic stroke in females with
Fabry disease.
3.6. Pain outcomes
3.6.1.1. Agalsidase alfa 0.2 mg/kg EOW. A prospective, open-label
single-arm CT showed significant decreases in Brief Pain Inventory
(BPI) ‘pain at its worst’ scores in 36 female patients (mean age 47
[range 14–76] years) who completed 48months of treatment with
agalsidase alfa [16]. In addition, three OS publications showed no
change or non-significant improvements in patient-reported pain scores
during treatment with agalsidase alfa [19,25,26]. In one publication,
nine female patients were followed for 51.5months [25], another
included a 27-year-old and a 41-year-old woman who were treated
for up to 1 year [19], and the last publication reported data in 78
females who started ERT at 49 years and received treatment for up to
4 years [26] (Supplementary Table 12).
In a MG OS publication including 11 female patients (aged
21–56 years), acroparaesthesiae decreased after 6months' treatment
with agalsidase alfa [72]. Another MG OS publication, including a total
of 752 patients (of whom 393 were female), showed that 36months of
treatment with agalsidase alfa resulted in significantly decreased pain
severity, though the measurements for ‘pain at its worst’ and ‘pain at its
least’ remained unchanged [22]. Three publications from two OS
publications in MG populations did not identify any changes in BPI
when patients were switched from agalsidase beta 1.0mg/kg EOW to
agalsidase alfa 0.2mg/kg EOW [49 (18 patients, a median of 1.3 years
after switch/dose reduction),[74] (seven female patients, mean age
52 years, pain data reported 12months after switching),[51]]. One CR
reported stable pain outcomes in the two female patients who received
agalsidase alfa (age at start of ERT 21 and 52 years, ERT duration 3.1
and 2.8 years, respectively) [53].
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3.6.1.2. Agalsidase beta 1.0 mg/kg EOW. One CR reported the
development of peripheral neuropathy (tingling in hands/feet,
temperature intolerance) when the 51-year-old patient was treated
with agalsidase beta [38]. A CR reported improved pain outcomes in
two female patients treated with agalsidase beta (age at ERT initiation
46 and 50 years, duration of ERT 10.3 and 11 years, respectively) [53].
3.6.1.3. Mixed ERT. One open-label, MG study in 18 patients, aged
8–51 years and mostly females, showed that 10months of treatment
with ERT resulted in significant decreases in neuropathic pain scales
scores (Douleur Neuropathique 4 and the Leeds Assessment of
Neuropathic Symptoms and Signs) in 13 treated patients [74]. One
OS publication of mixed ERT described reduction in pain in three out of
14 female patients on ERT and reported no change in intra-epidermal
nerve fibre density in the two females on ERT who agreed to undergo a
biopsy [55].
3.7. Gastrointestinal (GI) outcomes
3.7.1.1. Agalsidase alfa 0.2 mg/kg EOW. GI outcomes were reported in
female patients in two OS publications with agalsidase alfa [21,26]. The
first of these studies reported data from 25 female patients, including
paediatric patients, showing that abdominal pain was reduced after
24months of ERT, although the incidence of diarrhoea in female
patients had increased at this time point compared with baseline
levels [21]. The other OS publication reported non-significant
improvements in constipation and diarrhoea after 4 years of
treatment, compared with baseline in 78 females (age at ERT
initiation 49 years) [26] (Supplementary Table 13). In addition, one
CR of a 54-year-old female patient treated with agalsidase alfa in
combination with omeprazole also observed an improvement in GI
outcomes during 30months of ERT [29].
3.7.1.2. Agalsidase beta 1.0 mg/kg EOW. There were no publications
reporting changes in GI outcomes with agalsidase beta in female or MG
populations.
3.7.1.3. Mixed ERT. There were no publications reporting changes in
GI outcomes with mixed-ERT regimens.
3.8. Quality of life (QoL)
3.8.1.1. Agalsidase alfa 0.2 mg/kg EOW. QoL measures were reported in
two publications with agalsidase alfa, one from a single-arm open-label
CT [14], and one from a registry study [26]. The single-arm CT
presented QoL data after 27 weeks of ERT in 10 female patients
(mean age 45 [range 20–66] years) using the 36-item Short-Form
Health Survey (SF-36) [14]. Significant improvements were shown in
the overall summary component for physical functioning, as well as the
role-physical, and general health components of the SF-36 [14].
However, the OS publication did not report any significant changes in
5-dimension EuroQol questionnaire and visual analogue health scores
in 78 female patients during 4 years of ERT (age at ERT initiation
49 years) [26]. An OS publication described no change in self-reported
energy levels in the three female patients who received agalsidase alfa
[56] (Supplementary Table 14).
The two papers from the MG, long-term OS of the impact of
switching ERT regimen from agalsidase beta to agalsidase alfa reported
no changes in QoL (EuroQol dimensions; baseline mean [standard error
(SE)]: 1.0 [0.0]; 12months after switch mean [SE]: 0.9 [0.1]), but did
not report the data for females separately or show data beyond
12months [51,74].
3.8.1.2. Agalsidase beta 1.0 mg/kg EOW. For agalsidase beta, one Fabry
Registry study publication in 59 female patients (who started ERT at a
median age of 48 [range 16–71] years) treated for an average of
41months reported significant improvements in overall QoL, including
bodily pain, but with no consistent difference between the older and
younger female patients, and SF-36 mental summary score, but no
change in physical summary score [31] (Supplementary Table 14).
Another OS publication described no change in self-reported energy
levels in five patients who received reduced doses (0.5mg/kg EOW,
0.3 mg/kg EOW) of agalsidase beta (patients had been treated with the
approved 1.0mg/kg EOW dose for 74months before the dose
reduction) [56]. Also, a published case series of patients treated with
agalsidase beta reported that three female patients (aged 35, 64, and
67 years) had an improved ability to perform everyday tasks [37].
There was one MG OS publication describing significant improve-
ments in the SF-36 score with agalsidase beta. The study included 18
patients (nine females, age range 21–64 years) of whom 10 received
treatment (but the number of females receiving treatment was not
specified) [73].
3.8.1.3. Mixed ERT. One MG, open-label study of 18 patients, mostly
females, found that ERT treatment improved depression symptoms, as
measured by the Beck Depression Scale, Fatigue Severity Scale, and the
Pittsburgh Sleep Quality Index, after 10months of treatment (patients
aged 8–51 years) [75]. Similarly, one prospective MG OS publication,
including 14 females receiving treatment, found that patients who had
GFR levels> 60mL/min/1.73m2 at baseline generally showed lower
depression scores (as measured by the Center for Epidemiologic Studies
Depression Scale questionnaire) throughout the study period of 4 years.
Females with GFR scores< 60mL/min/1.73m2 at baseline tended to
show low depression scores in the first 2 years of follow-up, but these
scores increased during the third year of follow-up [55]. One OS
publication reported significant decreases in the SF-36 subscale scores
of general health and vitality but no change in SF-36 physical
functioning, role-physical, bodily pain, social functioning, role-
emotional, or mental health scores in 16 female patients who
switched from agalsidase beta to agalsidase alfa or to reduced-dose
agalsidase beta (median duration of treatment post-switch/dose
reduction was 1.3 years) [49].
4. Discussion
For many years, heterozygous females with Fabry disease were
thought to be only carriers of the disease. More recently, increasing
evidence has emerged that females with Fabry disease manifest clinical
symptoms and have a reduced life expectancy compared with healthy
subjects [1,2,16,81]; but they differ from classic male patients. First of
all, females with Fabry disease have a wider spectrum of disease se-
verity ranging from asymptomatic to severely affected phenotype
(rare). The pattern and severity of the organ involvement depends on
the GLA mutation [1,2,82] and the X-chromosome inactivation pattern
[80,83]. Secondly, females sometimes present with symptoms in a
single organ, rather than the multisystemic manifestations observed in
classic males [1,16,80,84]. Furthermore, contrary to males, females
may develop myocardial fibrosis before LVH, suggesting that LVH may
not be the only driver of cardiac disease burden in females.
Nevertheless, regardless of phenotype and clinical symptomatology,
female patients are not mere carriers of Fabry disease and may benefit
from receiving treatment. However, the scope of the literature re-
garding the effect of ERT specifically in female patients only has not
been previously explored or published. Therefore, this systematic lit-
erature review was conducted to analyse the effect of ERT on Fabry-
related outcomes specifically in female patients. We included all types
of publication with original data, any type of ERT regimen, and all
Fabry disease-related outcomes in the population of female Fabry pa-
tients over the past 16 years. The current article summarizes the out-
comes data available in females or MG studies in which>50% of the
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study population was female.
Our analysis covered 67 publications including six CTs. The data
suggest that ERT results in significant reductions in plasma and urine
GL-3 accumulation in women with elevated pre-treatment levels, and
improvements in cardiac parameters and QoL. These findings are si-
milar to trends identified in the male population [11]. In males, there
was improvement in some outcomes when the higher dose (1.0 mg/kg
EOW agalsidase beta) was administered and benefits to starting ERT
early [11]. In females, further studies are needed to clarify the re-
levance of ERT dose in female patients. With regard to timing of
treatment initiation, there is one observational registry study publica-
tion which showed that initiation of agalsidase beta earlier resulted in a
lower risk of clinical events in females [85]. Another analysis of the
Fabry Registry in over 400 females reported that the severe clinical
event rate was 14% and that the incidence of severe clinical events was
highest for the first 6months of agalsidase beta and declined thereafter
[86].
Our methodology does have limitations that are reviewed in detail
elsewhere [10]. Our analysis highlights the difference in the levels of
evidence between male and female patients with Fabry disease, how-
ever, we acknowledge that, due to the rare nature of Fabry disease,
patient populations are small and the amount of level 1/grade A evi-
dence from CTs is limited. For example, data in females were often
derived from small OS or CRs. Another limitation may result from the
likelihood of individual patients included in multiple studies. For ex-
ample, when registry data were reported in different publications, it is
likely that patient data were reported more than once. Also, there was
limited information available on certain outcomes (nervous system, GI,
and pain), and short-term studies did not always capture changes in
female patients with mild disease progression. In fact, for GI symptoms,
a recent analysis of the Fabry Registry reported data for abdominal pain
and diarrhoea at baseline and following 2.5 years of agalsidase beta
therapy in 168 female Fabry patients. They reported that 45% had
abdominal pain and 39% had diarrhoea at baseline, which decreased
significantly following treatment, to 31% and 27%, respectively
(p < 0.01 for both) [87]. Based on natural history observations in fe-
male patients, kidney variables such as proteinuria, albuminuria, and
eGFR are unlikely to deteriorate significantly over 1–3 years of follow-
up) [11,88]. Therefore, to fully understand the effect of ERT in female
Fabry patients, there is a need to perform clinical studies and examine a
broad range of relevant outcomes for an extended duration of time.
Furthermore, we urge researchers collating and publishing data on MG
populations to include a breakdown of outcomes for males and females
separately, so that readers and prescribers can determine any sex-spe-
cific effects.
Few publications described the nature of the genetic variants or the
underlying disease severity for all female patients studied. In particular,
no paper included data on X-chromosome inactivation patterns.
Differences in X-chromosome inactivation patterns may have resulted
in heterogeneous female study populations. A skewed X-chromosome
inactivation pattern with a predominant expression of the mutant allele
is associated with a more severe disease phenotype [80] and as a
consequence may also impact on the responses that can be expected
following treatment with ERT. X-chromosome inactivation patterns can
be determined by analysing the methylation status at the HUMARA
locus using two biological samples, preferably peripheral leukocytes
and buccal smear cells [80,89]. For future research, we encourage re-
porting of the GLA variant and the pattern of X-chromosome inactiva-
tion in order to provide context for ERT-treatment effects.
In conclusion, female patients with Fabry disease often have clinical
manifestations but can only benefit from receiving treatment if the
disease has been diagnosed. Similar to male patients, ERT has a positive
effect on GL-3 levels and cardiac outcomes. However, as Fabry disease
manifestations in females are more heterogeneous compared with
classic males, there is a need to develop gender-specific therapeutic
guidelines and goals of ERT. Furthermore, reporting information
regarding the nature of the Fabry GLA variant and the X-chromosome
inactivation profile (random or skewed) will help the interpretation of
ERT treatment effects in female patients with classic and later-onset
Fabry disease.
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